Abstract
The molecular docking, synthesis, spectral characterization and anti-tubercular evaluation of 10 novel N’-substituted-6-hydroxy-2,5,7,8-tetramethylchroman-2-carbohydrazide derivatives (SM1-SM10) were reported. The structures of the synthesized derivatives were affirmed by spectroscopic studies such as FTIR, 1H NMR, 13C NMR and high resolution-mass spectrometry. Predicted ADME and toxicity investigations were accomplished to presume the pharmacokinetic parameters of the compounds. The synthesized compounds were evaluated for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv strain using Microplate Alamar Blue Assay (MABA) taking isoniazid, rifampicin, ethambutol, amikacin, streptomycin and levofloxacin as positive drug standards. Compound SM8 has shown the significant anti-tubercular activity among all the titled compounds. The results indicated that chroman-hydrazone skeleton could serve as a lead for the development of novel anti-tubercular drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
